Draft:Onder Albayram
 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 3,283 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Onder Albayram | |
|---|---|
| [[File:File .png|frameless|alt=Onder Albayram|upright=1]] | |
| Born | 12 March 1980 (age 44) Gaziantep, Turkey |
| Nationality | Turkish, American |
| Alma mater | University of Southern California (MSc), Bonn University (PhD) |
| Known for | Traumatic brain injury, Chronic traumatic encephalopathy, Dementia |
| Awards | Alzheimer's Association Research Fellowship Award (2016) |
| Scientific career | |
| Fields | Neuroscience, Neuropharmacology, Molecular Biology |
| Institutions | MRC Laboratory of Molecular Biology, University of Cambridge, University of Southern California, Bonn University, Harvard Medical School, Medical University of South Carolina |
Onder Albayram (born March 12, 1980) is a Turkish-American neuroscientist and neuropharmacologist. He is an Assistant Professor of Pathology and Neuroscience at the Medical University of South Carolina in Charleston, SC, USA. His research focuses on interdisciplinary approaches integrating his background and research interests in aging brain and dementia. He studies the different involvement of innate neuroprotective mechanisms in the physiology of young and aged brains, as well as pathological conditions relevant to cerebrovascular and trauma-related disorders.
Biography[edit]
His journey into the realm of research training commenced during his undergraduate years at the MRC Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK[1]. There, he was involved in a study exploring the sensory ability of the nematode organism Caenorhabditis elegans, which played a crucial role in discovering how the animal integrates signals from food and hypoxic stress to regulate its sensorimotor circuitry[2]. In 2008, he completed his master's in pharmaceutical sciences at the University of Southern California, Los Angeles, USA, with a thesis titled "Molecular genetic mechanisms of schizophrenia and pharmacogenetic characterizations."[3]
In 2009, he joined the Institute of Molecular Psychiatry Ph.D. program at the University of Bonn in Germany. His research focused on the molecular and cellular mechanisms of age-dependent changes in the endocannabinoid system and their effects on long-lasting neuro-immune adaptations. This research led to the discovery of the crucial role of Cannabinoid receptor 1 -expressed GABAergic neurons in regulating microglial activity and its protective function in aging brain[4] [5]. Albayram also equally contributed to the discovery that low doses of Δ9-tetrahydrocannabinol (THC) appeared to rejuvenate aged brains by restoring deficits in cannabinoid signaling, contrary to its documented detrimental effects in young brains[6] [7]. This finding was published as a cover story in Nature Medicine and has been recognized by numerous press outlets, including Scientific American[8], The Guardian[9], Inverse[10], News Week[11], Alzheimer’s Forum[12].
After completing his research training in neurobiology related to brain aging in Europe, Albayram joined Harvard Medical School in 2014, which developed novel tests to identify a specific form of the phosphorylated axonal protein tau (cis P-tau) as a precursor to traumatic brain injury (TBI) and related-dementia[13]. Albayram received the Alzheimer’s Association Research Fellowship Award in 2016[14] and recently published research connecting vascular insults to vascular cognitive impairment[15] [16].
Albayram and colleagues recently discovered a transporter called p17 that induces mitophagy, eliminating damaged mitochondrion and promoting neuronal survival. This mechanism could help prevent age-dependent neurodegeneration[17] and TBI[18] [19].
Recently, Albayram's laboratory has demonstrated a progressive age-related cervical lymph node atrophy and thickening of lymphatics channels in the human brain's dorsal and ventral regions[20]. These findings reflect the reduced lymphatic output of the aged brain, which results in deleterious immune and neuroinflammatory responses that contribute to the development and progression of age-dependent neurological disorders such as Alzheimer's disease and related dementias[21] [22].
References[edit]
- ^ "Bilim Yolunda Adım Adım İlerliyor: Onder Albayram". TUBITAK, Bilim ve Teknik, 2005.
- ^ "Experience-Dependent Modulation of C. elegans Behavior by Ambient Oxygen". Current Biology, 2005.
- ^ "Molecular Genetic Mechanisms of Schizophrenia and Pharmacogenetic Characterizations". USC Libraries Dissertation Publishing; Los Angeles, CA, USA, 2008.
- ^ Albayram, Onder; Alferink, Judith; Pitsch, Julika; Piyanova, Anastasia; Neitzert, Kim; Poppensieker, Karola; Mauer, Daniela; Michel, Kerstin; Legler, Anne; Becker, Albert; Monory, Krisztina; Lutz, Beat; Zimmer, Andreas; Bilkei-Gorzo, Andras (2011). "Role of CB1 Cannabinoid Receptors on GABAergic Neurons in Brain Aging". Proceedings of the National Academy of Sciences (PNAS), 2011. 108 (27): 11256–11261. Bibcode:2011PNAS..10811256A. doi:10.1073/pnas.1016442108. PMC 3131310. PMID 21690345.
- ^ "Schutz vor Demenz: Bodyguard für das Gehirn". FOCUS, 2014.
- ^ Bilkei-Gorzo, Andras; Albayram, Onder; Draffehn, Astrid; Michel, Kerstin; Piyanova, Anastasia; Oppenheimer, Hannah; Dvir-Ginzberg, Mona; Rácz, Ildiko; Ulas, Thomas; Imbeault, Sophie; Bab, Itai; Schultze, Joachim L.; Zimmer, Andreas (2017). "A Chronic Low Dose of Δ9-tetrahydrocannabinol (THC) Restores Cognitive Function in Old Mice". Nature Medicine (Cover Story), 2017. 23 (6): 782–787. doi:10.1038/nm.4311. PMID 28481360.
- ^ Ozaita, Andrés; Aso, Ester (2017). "The Cannabis Paradox: When Age Matters". Nature Medicine, News & Views, 2017. 23 (6): 661–662. doi:10.1038/nm.4348. hdl:10230/32452. PMID 28586333.
- ^ "Marijuana May Boost, Rather Than Dull, the Elderly Brain". Scientific American, 2017.
- ^ Sample, Ian (8 May 2017). "Daily Dose of Cannabis Extract Could Reverse Brain's Decline in Old Age, Study Suggests". The Guardian, 2017.
- ^ "Marijuana Reversed the Effects of Old Age in Mouse Brains". INVERSE, 2017. 8 May 2017.
- ^ "Can Marijuana Restore Memory? New Study Shows Cannabis Can Reverse Cognitive Decline in Mice". Newsweek, 2017. 8 May 2017.
- ^ "Only in Old Mice, a Touch of Cannabinoid Helps Memory". Alzheimer’s Association Forum, 2017.
- ^ Albayram, Onder; Kondo, Asami; Mannix, Rebekah; Smith, Colin; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Qiu, Jianhua; Monuteaux, Michael; Driver, Jane; Yan, Sandra; Gormley, William; Puccio, Ava M.; Okonkwo, David O.; Lucke-Wold, Brandon; Bailes, Julian; Meehan, William; Zeidel, Mark; Lu, Kun Ping; Zhou, Xiao Zhen (2017). "Cis P-tau is Induced in Clinical and Preclinical Brain Injury and Contributes to Post-Injury Sequelae". Nature Communications, 2017. 8 (1): 1000. Bibcode:2017NatCo...8.1000A. doi:10.1038/s41467-017-01068-4. PMC 5645414. PMID 29042562.
- ^ "Onder Albayram has been awarded an Alzheimer's Association Research Fellowship". Turkish American Scientists & Scholars Association, 2017.
- ^ Qiu, Chenxi; Albayram, Onder; Kondo, Asami; Wang, Bin; Kim, Nami; Arai, Ken; Tsai, Cheng-Yu; Bassal, Mahmoud A.; Herbert, Megan K.; Washida, Kazuo; Angeli, Peter; Kozono, Shingo; Stucky, Joseph E.; Baxley, Sean; Lin, Yu-Min; Sun, Yan; Rotenberg, Alexander; Caldarone, Barbara J.; Bigio, Eileen H.; Chen, Xiaochun; Tenen, Daniel G.; Zeidel, Mark; Lo, Eng H.; Zhou, Xiao Zhen; Lu, Kun Ping (2021). "Cis P-tau Underlies Vascular Contribution to Cognitive Impairment and Dementia and can be Effectively Targeted by Immunotherapy in Mice". Science Translational Medicine, 2021. 13 (596). doi:10.1126/scitranslmed.aaz7615. PMC 8272885. PMID 34078745.
- ^ "MUSC, Harvard Research Shows Promise in Alzheimer's and Dementia Treatment". The Post & Courier, 2021. 5 July 2021.
- ^ Oleinik, Natalia; Albayram, Onder; Kassir, Mohamed Faisal; Atilgan, F. Cansu; Walton, Chase; Karakaya, Eda; Kurtz, John; Alekseyenko, Alexander; Alsudani, Habeeb; Sheridan, Megan; Szulc, Zdzislaw M.; Ogretmen, Besim (2023). "Alterations of Lipid-Mediated Mitophagy Result in Aging-Dependent Sensorimotor Defects". Aging Cell, 2023. 22 (10): e13954. doi:10.1111/acel.13954. PMC 10577547. PMID 37614052.
- ^ "New Compound Shows Early Promise for Treatment of Lou Gehrig's Disease in Preclinical Models". EurekAlert (AAAS), 2023.
- ^ "p17/C18-Ceramide–Mediated Mitophagy is an Endogenous Neuroprotective Response in Preclinical and Clinical Brain Injury". PNAS Nexus, 2024.
- ^ "Drug Could Protect Brains from Damage After Concussions". EurekAlert (AAAS), 2024.
- ^ Albayram, Mehmet Sait; Smith, Garrett; Tufan, Fatih; Tuna, Ibrahim Sacit; Bostancıklıoğlu, Mehmet; Zile, Michael; Albayram, Onder (2022). "Non-invasive MR Imaging of Human Brain Lymphatic Networks with Connections to Cervical Lymph Nodes". Nature Communications, 2012. 13 (1): 203. Bibcode:2022NatCo..13..203A. doi:10.1038/s41467-021-27887-0. PMC 8752739. PMID 35017525.
- ^ "A First Glimpse of the Human Brain's Drains". EurekAlert (AAAS), 2022.